Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SDCBP | O00560 | 2/20 | 0.43 |
| ▸ | SDC2 | P34741 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468146 | 0.88 | ERAP1 (0.48) | EGLN1PYGLTACR3WDR5MEN1 | |
| SCHEMBL12467113 | 0.86 | MMP9 (0.45) | EGLN1MMP2MMP1MMP3MMP7 | |
| SCHEMBL485720 | 0.80 | EGLN1 (0.46) | EGLN1TSHRSDCBPSDC2PYGL | |
| SCHEMBL485718 | 0.80 | EGLN1 (0.46) | EGLN1TSHRSDCBPSDC2PYGL | |
| SCHEMBL12468152 | 0.79 | WDR5 (0.47) | EGLN1PYGLTACR3WDR5MEN1 | |
| SCHEMBL25388151 | 0.77 | PLK1 (0.57) | EGLN1MMP3PYGLCYP2C9MEN1 | |
| SCHEMBL25386182 | 0.77 | PLK1 (0.57) | EGLN1MMP3PYGLCYP2C9MEN1 | |
| SCHEMBL735538 | 0.77 | PLK1 (0.57) | EGLN1MMP3PYGLCYP2C9MEN1 | |
| SCHEMBL12728872 | 0.76 | ERAP1 (0.55) | WDR5 | |
| SCHEMBL9464737 | 0.71 | POLB (0.53) | EGLN1CCR1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283479-B2 | CXCR2 inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| US-20110184177-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-7919628-B2 | 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-05 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184177-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | EGLN1 1944/4885TSHR 1709/4885SDCBP 2173/4885 |
| US-20080090854-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | EGLN1 1944/4885TSHR 1709/4885SDCBP 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.